Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Ricardo Ribas(Institute of Cancer Research), Lesley‐Ann Martin(Institute of Cancer Research)

Breast Cancer Research

October 30, 2014

10.1186/s13058-014-0447-1

Cited by 26

Related Papers

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

|Breast Cancer Research|2012|43

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

|Breast Cancer Research|2012|33

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

|npj Breast Cancer|2022|16